Articles Tagged With:
-
FDA Actions
In this section: FDA approves new amyotrophic lateral sclerosis, expands the indication for pembrolizumab, adds giant cell arteritis to the indication for tocilizumab, and green lights generic ADHD drug.
-
Ohio Attorney General Files Suit Against 5 Pharmaceutical Companies Over Opioids
The suit alleges fraudulent marketing that misled the state, prescribers, and patients about the risks of these medications.
-
Investigators Conclude Long-term Opioid Use Increases Dependency and Overdose Risks
Nationwide epidemic has raised questions regarding the long-term use of such medication for chronic pain conditions.
-
Researchers Offer Remedies for FDA’s Accelerated Approval Program
Once a drug receives accelerated approved, manufacturers are free to charge whatever they believe the market will bear without evidence that the drug affects disease progression.
-
Efficacy of Cephalexin Monotherapy for Cellulitis
Data support the use of cephalexin treatment as a simpler, less expensive antimicrobial regimen.
-
Desmopressin Nasal Spray for Treatment of Nocturia: Proceed with Caution
Because desmopressin can result in serious adverse events, it is important that clinicians become fully familiar with FDA labeling.
-
Combination Treatment for Hospitalized Influenza
Patients admitted with confirmed influenza A and who were randomized to oseltamivir plus clarithromycin and naproxen demonstrated a dramatic improvement.
-
Send Polycystic Ovary Syndrome Patients to the Dentist?
In seven studies, there was a positive association between polycystic ovary syndrome and periodontal disease.
-
Testosterone Replacement: The Limitations of ‘Dr. Google’
Clinicians may have to take a role in directing patients toward high-quality online information.
-
The Ever-evolving Status of Prostate Cancer Screening
Each patient must decide whether he is willing to shoulder the risks associated with prostate cancer screening.